PROGEN.ST STO
Prostatype Genomics AB (publ)
1W: -22.6%
1M: -35.6%
3M: -57.3%
YTD: -92.4%
1Y: -86.5%
3Y: -100.0%
5Y: -100.0%
kr 0.09 ($0.01)
-0.00 (-2.33%)
Weekly Expected Move ±15.2%
kr 0
kr 0
kr 0
kr 0
kr 0
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$594K
+198.5% ▲
5Y CAGR: -2.8%
Gross Profit
-$38M
-2061.2% ▼
Operating Income
-$39M
+4.3% ▲
Net Income
-$45M
-8.4% ▼
EPS (Diluted)
$-1.32
+90.3% ▲
EBITDA
-$37M
+1.3% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $10K | $683K | $1M | $199K | $594K |
| YoY Growth | -98.5% | +6730.0% | +98.5% | -85.3% | +198.5% |
| Cost of Revenue | -$2M | $13M | -$2M | -$2M | $38M |
| Gross Profit | $3M | $683K | $4M | $2M | -$38M |
| Gross Margin | 25096.4% | 100.0% | 274.9% | 963.8% | -6332.7% |
| R&D Expenses | $1M | $4M | $3M | $2M | $1M |
| SG&A Expenses | $8M | $13M | $18M | $16M | $0 |
| Operating Expenses | $18M | $29M | $43M | $43M | $1M |
| Operating Income | -$16M | -$29M | -$39M | -$41M | -$39M |
| Operating Margin | -155482.6% | -4200.4% | -2894.3% | -20529.1% | -6579.1% |
| Interest Expense | $81K | $397K | $2M | $2M | $2M |
| Income Before Tax | -$16M | -$29M | -$41M | -$41M | -$45M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$16M | -$29M | -$41M | -$41M | -$45M |
| Net Margin | -156297.6% | -4258.7% | -3055.7% | -20628.6% | -7492.1% |
| EPS (Diluted) | $-10.64 | $-7.72 | $-12.04 | $-13.67 | $-1.32 |
| EBITDA | -$15M | -$27M | -$38M | -$37M | -$37M |
| Shares Outstanding | 1M | 4M | 3M | 3M | 34M |